News

News 15.01.2026 Unlike typical award programs, this recognition is based entirely on platform performance metrics, reflecting real activity and real outcomes across global R&D teams. Over the past year, scientists requested and completed studies spanning: 🔹 in vitro toxicology 🔹 pharmacology and assay development 🔹 cell culture and characterization All delivered through an on-demand procurement workflow. Performance indicators...

News 14.01.2026 Zurich, Switzerland - 13.01.2026 Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium - bringing together academic institutions, industry partners, SMEs and patient organisations - is a five-year...

News 13.01.2026 Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™,...

News 12.01.2026 Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled ‘Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life...

News 12.01.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update...